Results

1–10 of 12 results for Nonproliferative Diabetic Retinopathy

Progression to Proliferative Diabetic Retinopathy in Nonproliferative Diabetic Retinopathy Eyes Without Diabetic Macular Edema in the United States
Ehsan Rahimy, MD
Annual Meeting Talks
2020
Insights Into the Progression of Diabetic Retinopathy Severity Among Primary Care Patients With Diabetes in the United States
Geeta A. Lalwani, MD
Annual Meeting Talks
2020
Intravitreal Aflibercept Injection for Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Study
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2020
Long-term Clinical Impact of Intravitreal anti-VEGF Therapy for Severe Non-proliferative Diabetic Retinopathy (NPDR): Analyses Through a Discrete Event Simulation Model
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2021
A Randomized Trial of Intravitreous Anti-VEGF for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W)
Raj K. Maturi, MD
Updates from the Field
2021
Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy With Intravitreal Aflibercept Injection: 52-Week Results From PANORAMA
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2019
Episode 151: Novel Understanding of Diabetic Retinopathy with Dr. Thomas Gardner
Jayanth Sridhar, MD
Member Podcasts
2018
Ranibizumab Induces Regression of Diabetic Retinopathy
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2016
Retinal Nonperfusion and Anti-VEGF Therapy in Diabetic Retinopathy: What We Know and What We Don’t Know
Dante Joseph Pieramici, MD
Updates from the Field
2017
Improvement of Worsening in Diabetic Retinopathy Through 2 Years in a Randomized Trial
Susan B. Bressler, MD, FASRS
Updates from the Field
2017